Trial Outcomes & Findings for Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease (NCT NCT03978130)
NCT ID: NCT03978130
Last Updated: 2025-06-06
Results Overview
Change in 6MWD, reflective of functional capacity, is measured by the 6-minute walk test (6MWT). The 6-minute walk test (6MWT) is a submaximal exercise test in which the pace is self-selected by the participant. The 6MWT will be performed during baseline hospitalization and at the 3-month follow-up visit by a blinded research nurse. The outcome change in 6MWD is calculated as 3 month 6MWD minus baseline 6MWD.
COMPLETED
NA
400 participants
Baseline, 3 months
2025-06-06
Participant Flow
Participant milestones
| Measure |
mHealth-CR
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
Participants in this arm receive usual care.
|
|---|---|---|
|
Overall Study
STARTED
|
298
|
102
|
|
Overall Study
COMPLETED
|
271
|
85
|
|
Overall Study
NOT COMPLETED
|
27
|
17
|
Reasons for withdrawal
| Measure |
mHealth-CR
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
Participants in this arm receive usual care.
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
13
|
14
|
|
Overall Study
Withdrawal by Subject
|
12
|
2
|
|
Overall Study
Adverse Event
|
2
|
1
|
Baseline Characteristics
Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease
Baseline characteristics by cohort
| Measure |
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=102 Participants
Participants in this arm receive usual care.
|
Total
n=400 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
71 years
n=99 Participants
|
71 years
n=107 Participants
|
71 years
n=206 Participants
|
|
Sex: Female, Male
Female
|
82 Participants
n=99 Participants
|
27 Participants
n=107 Participants
|
109 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
216 Participants
n=99 Participants
|
75 Participants
n=107 Participants
|
291 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
23 Participants
n=99 Participants
|
11 Participants
n=107 Participants
|
34 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
275 Participants
n=99 Participants
|
91 Participants
n=107 Participants
|
366 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
11 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
27 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
36 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
229 Participants
n=99 Participants
|
74 Participants
n=107 Participants
|
303 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
31 Participants
n=99 Participants
|
13 Participants
n=107 Participants
|
44 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
298 participants
n=99 Participants
|
102 participants
n=107 Participants
|
400 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline, 3 monthsChange in 6MWD, reflective of functional capacity, is measured by the 6-minute walk test (6MWT). The 6-minute walk test (6MWT) is a submaximal exercise test in which the pace is self-selected by the participant. The 6MWT will be performed during baseline hospitalization and at the 3-month follow-up visit by a blinded research nurse. The outcome change in 6MWD is calculated as 3 month 6MWD minus baseline 6MWD.
Outcome measures
| Measure |
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=102 Participants
Participants in this arm receive usual care.
|
Persistently High
Participants who had continuously high engagement with the program.
|
|---|---|---|---|
|
Change in 6-minute Walking Distance (6MWD)
|
41.2 meters
Standard Deviation 1.5
|
25.6 meters
Standard Deviation 2.7
|
—
|
PRIMARY outcome
Timeframe: 3 monthsWeekly engagement will be measured as the fraction of the following 11 elements completed each week: (1-7) daily entry of exercise data and relative perceived exertion (RPE); (8) completed weekly phone call with exercise therapist; (9) at least one electronic communication with exercise therapist; (10) watching educational video (which will vary by week); and (11) at least one home BP measurement. Engagement will be assessed as a pseudo-continuous outcome, as the score can range from 0% (0 activities completed) to 100% (all 11 activities completed). The participants in the intervention arm will be grouped into 3 engagement phenotypes based on their scores: 1) Persistently Low, 2) Intermediate Declining, and 3) Persistently High.
Outcome measures
| Measure |
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=298 Participants
Participants in this arm receive usual care.
|
Persistently High
n=298 Participants
Participants who had continuously high engagement with the program.
|
|---|---|---|---|
|
Number of Participants in Each Engagement Phenotype on Intervention Arm
|
81 Participants
|
93 Participants
|
124 Participants
|
SECONDARY outcome
Timeframe: 3 monthsUsing the SMART goal framework, GAS describes the person's expected level of goal achievement over 3 months, ranging from no change (scored as -2) to much better than expected (scored as +2) out of a 5 point-scale. Scales are dynamically set according to a person's needs, while measurement of attainment is standardized. Overall score is calculated by incorporating the goal of outcomes scores into an aggregated t-score. Goal attainment, through goal setting, is an especially important outcome in older adults who may begin an intervention with a variety of deficits (therefore necessitating individualized therapy towards realistic goals).
Outcome measures
| Measure |
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=102 Participants
Participants in this arm receive usual care.
|
Persistently High
Participants who had continuously high engagement with the program.
|
|---|---|---|---|
|
Percentage of Participants With Goal Attainment, as Measured Using a 5-point Goal Attainment Scale (GAS)
|
25.7 Percentage of participants
|
20.9 Percentage of participants
|
—
|
SECONDARY outcome
Timeframe: Month 3The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. For the SF-12, the 3 month score will be analyzed using a threshold of 5 points in SF-12 physical component score (PCS) as a clinically meaningful change.
Outcome measures
| Measure |
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=102 Participants
Participants in this arm receive usual care.
|
Persistently High
Participants who had continuously high engagement with the program.
|
|---|---|---|---|
|
12-Item Short Form Survey (SF-12) Score
|
46.3 score on a scale
Standard Deviation 1
|
48.2 score on a scale
Standard Deviation 1.1
|
—
|
SECONDARY outcome
Timeframe: Baseline, 3 monthsThe Seattle Angina Questionnaire-7 (SAQ-7) is a self-administered questionnaire that measures patient-reported health measures related to coronary artery disease (CAD). The SAQ-7 is scored from 0 to 100, with higher scores indicating better health status, less frequent angina, and better quality of life (0-24: Poor health status; 25-49: Fair; 50-74: Good; 75-100: Excellent). For SAQ-7, we will analyze at a single time point (3 months) the number of participants who have residual angina (SAQ-7\<100) vs. no angina (SAQ-7=100).
Outcome measures
| Measure |
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=102 Participants
Participants in this arm receive usual care.
|
Persistently High
Participants who had continuously high engagement with the program.
|
|---|---|---|---|
|
Percentage of Participants With no Residual Angina, as Measured by the Seattle Angina Questionnaire 7 (SAQ-7) (Disease-specific Health Status)
|
25.7 Percentage of participants
|
20.9 Percentage of participants
|
—
|
SECONDARY outcome
Timeframe: Baseline, 3 monthsDefined as any improvement or worsening in basic (BADLs) or instrumental (IADLs) over 3 months. The Bristol Activities of Daily Living Scale (BADL) measures basic self-care behaviors: feeding, toileting, bathing, dressing, and ambulating. The score is interpreted based on the total score, which ranges from 0 to 60. Higher scores indicate greater independence in daily living activities. The Lawton Instrumental Activities of Daily Living (IADL) scale measures activities that allow a person to live independently (e.g. food preparation, medication management, transportation, shopping, managing finances, using the telephone, and housekeeping). The total score ranges from 0 (low function, dependent) to 8 (high function, independent) for women, and 0 through 5 for men.
Outcome measures
| Measure |
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=102 Participants
Participants in this arm receive usual care.
|
Persistently High
Participants who had continuously high engagement with the program.
|
|---|---|---|---|
|
Percentage of Participants Who Have Any ADL or IADL Impairment
|
9.7 percentage of participants
|
10.6 percentage of participants
|
—
|
SECONDARY outcome
Timeframe: 1 YearDefined as number of participants who were readmitted into the hospital with an overnight stay (including observation) in any hospital within 12 months of hospitalization. Data are obtainable via the electronic health record (EHR).
Outcome measures
| Measure |
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=102 Participants
Participants in this arm receive usual care.
|
Persistently High
Participants who had continuously high engagement with the program.
|
|---|---|---|---|
|
Number of Hospital Readmissions
|
56 Participants
|
16 Participants
|
—
|
SECONDARY outcome
Timeframe: 1 YearData are obtainable via the electronic health record (EHR).
Outcome measures
| Measure |
mHealth-CR
n=298 Participants
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=102 Participants
Participants in this arm receive usual care.
|
Persistently High
Participants who had continuously high engagement with the program.
|
|---|---|---|---|
|
Number of Participants Who Died From Any Cause
|
5 Participants
|
1 Participants
|
—
|
Adverse Events
mHealth-CR
Usual Care
Serious adverse events
| Measure |
mHealth-CR
n=298 participants at risk
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=102 participants at risk
Participants in this arm receive usual care.
|
|---|---|---|
|
Musculoskeletal and connective tissue disorders
Fall
|
0.67%
2/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Investigations
Abnormal labs
|
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Renal and urinary disorders
Urinary obstruction
|
0.00%
0/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.98%
1/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Surgical and medical procedures
Planned procedure
|
0.00%
0/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.98%
1/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Immune system disorders
Cancer
|
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Musculoskeletal and connective tissue disorders
Dizziness
|
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Respiratory, thoracic and mediastinal disorders
COVID
|
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Gastrointestinal disorders
GI Issues
|
1.0%
3/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Gastrointestinal disorders
Difficulty Swallowing
|
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Cardiac disorders
Chest pain, tightness, angina
|
0.67%
2/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Cardiac disorders
Planned procedure
|
0.67%
2/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.98%
1/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Cardiac disorders
Heart Failure
|
0.34%
1/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Cardiac disorders
Myocardial Infarction
|
0.00%
0/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.98%
1/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Cardiac disorders
Arrythmia, claudication, hypertensive or hypotensive urgency
|
1.3%
4/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.00%
0/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
Other adverse events
| Measure |
mHealth-CR
n=298 participants at risk
Participants in this arm will receive the mHealth-CR intervention.
mHealth-CR: Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
|
Usual Care
n=102 participants at risk
Participants in this arm receive usual care.
|
|---|---|---|
|
Cardiac disorders
Cardiac related events (Chest pain, planned procedure, and other)
|
8.1%
24/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
10.8%
11/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Musculoskeletal and connective tissue disorders
Body pain
|
3.7%
11/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
2.9%
3/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Musculoskeletal and connective tissue disorders
Fall
|
2.7%
8/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
0.98%
1/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
|
Investigations
Other events
|
7.0%
21/298 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
2.9%
3/102 • Adverse Events monitored/assessed for 3 months. All-Cause Mortality monitored/assessed through follow up, up to 1 year.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place